# Elfabrio

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/elfabrio
Canonical HTML page: https://getyourbrief.com/entity/elfabrio

## Recent coverage (2 stories, network-wide)

### Protalix BioTherapeutics Misses Q4 Estimates, Sets Conservative FY26 Outlook
2026-03-18 11:13:37 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protalix BioTherapeutics reported a dual miss on revenue and earnings for the latest quarter, reflecting ongoing challenges in the commercial ramp-up of its Fabry disease treatment. Despite the shortfall, the company provided a new fiscal year 2026 outlook as it continues to leverage its plant-based protein expression platform.
Full story: https://getbiobrief.com/story/protalix-biotherapeutics-earnings-miss-fy26-outlook

### Protalix BioTherapeutics Misses FY26 Estimates Amid Biotech Market Volatility
2026-03-18 11:11:27 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protalix BioTherapeutics reported misses on both top-line and bottom-line estimates for the fiscal year 2026, reflecting ongoing challenges in the rare disease therapeutic market. Despite the shortfall, the company provided a forward-looking outlook for FY26, signaling a focus on long-term clinical development and commercialization of its plant-based protein expression platform.
Full story: https://gethealthbrief.com/story/protalix-biotherapeutics-fy26-earnings-miss

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.